Diagnostic accuracy of biomarkers measured in the hepatic vein and peripheral vein in the prediction of advanced fibrosis in patients with chronic viral hepatitis

Clinical Biochemistry

Volumn 45, Issue 13-14, 2012, Pages 1075-1080

  Suk, Ki Tae ^a   Kim, Dong Joon ^a   Kim, Chang Hoon ^b   Park, Seung Ha ^c   Cheong, Jae Youn ^d   Cho, Sung Won ^d   Choi, Jong Young ^e   Han, Kwang Hyub ^f   Sung, Ho Taik ^g   Hong, So Hyung ^a   Kim, Dae Yong ^a   Yoon, Jai Hoon ^a   Kim, Yeon Soo ^a   Baik, Gwang Ho ^a   Kim, Jin Bong ^a  

^a Hallym University College of Medicine   (South Korea)

^b State University of New York Upstate Medical University: College of Medicine   (United States)

^c Inje University College of Medicine   (South Korea)

^d Ajou University School of Medicine   (South Korea)

^e The Catholic University of Korea College of Medicine   (South Korea)

^f Yonsei University College of Medicine   (South Korea)

^g STANFORD UNIVERSITY   (United States)

Author keywords

Biological markers; Diagnosis; Extracellular matrix; Hepatic veins; Liver fibrosis

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN A1; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; GELATINASE A; HAPTOGLOBIN; HYALURONIC ACID; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HEPATIC VEIN; HEPATITIS B; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PERIPHERAL VEIN; PORTAL VEIN BLOOD PRESSURE; PREDICTIVE VALUE; PRESSURE GRADIENT; PRIORITY JOURNAL;

ADULT; APOLIPOPROTEIN A-I; AREA UNDER CURVE; BIOLOGICAL MARKERS; BIOPSY, FINE-NEEDLE; FEMALE; HAPTOGLOBINS; HEPACIVIRUS; HEPATIC VEINS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LOGISTIC MODELS; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROCOLLAGEN; PROSPECTIVE STUDIES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 84866024116     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.04.031     Document Type: Article

References (37)

1. Friedman S.L. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008, 134:1655-1669.
2. Barascuk N., Veidal S.S., Larsen L., et al. A novel assay for extracellular matrix remodeling associated with liver fibrosis: an enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagen. Clin Biochem 2010, 43:899-904.
3. Cales P., Veillon P., Konate A., et al. Reproducibility of blood tests of liver fibrosis in clinical practice. Clin Biochem 2008, 41:10-18.
4. Arthur M.J. Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. Gastroenterology 2002, 122:1525-1528.
5. Ramachandran P., Iredale J.P. Reversibility of liver fibrosis. Ann Hepatol 2009, 8:283-291.
6. Paik Y.H., Brenner D.A. NADPH oxidase mediated oxidative stress in hepatic fibrogenesis. Korean J Hepatol 2011, 17:251-257.
7. Jiao J., Friedman S.L., Aloman C. Hepatic fibrosis. Curr Opin Gastroenterol 2009, 25:223-229.
8. Regev A., Berho M., Jeffers L.J., et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002, 97:2614-2618.
9. Hongbo L., Xiaohui L., Hong K., Wei W., Yong Z. Assessing routine and serum markers of liver fibrosis in CHB patients using parallel and serial interpretation. Clin Biochem 2007, 40:562-566.
10. Cales P., Boursier J., Bertrais S., et al. Optimization and robustness of blood tests for liver fibrosis and cirrhosis. Clin Biochem 2010, 43:1315-1322.
11. Cross T.J., Calvaruso V., Maimone S., et al. Prospective comparison of Fibroscan, King's score and liver biopsy for the assessment of cirrhosis in chronic hepatitis C infection. J Viral Hepat 2010, 17:546-554.
12. Bosch J., Abraldes J.G., Berzigotti A., Garcia-Pagan J.C. The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol 2009, 6:573-582.
13. Gressner O.A., Weiskirchen R., Gressner A.M. Biomarkers of liver fibrosis: clinical translation of molecular pathogenesis or based on liver-dependent malfunction tests. Clin Chim Acta 2007, 381:107-113.
14. Naveau S., Gaude G., Asnacios A., et al. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology 2009, 49:97-105.
15. Yilmaz Y., Ulukaya E., Dolar E. The quest for liver fibrosis biomarkers: promises from the enhanced liver fibrosis panel and beyond. Hepatology 2009, 49:1056-1057.
16. Bedossa P., Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996, 24:289-293.
17. Hanley J.A., McNeil B.J. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983, 148:839-843.
18. Svegliati-Baroni G., De Minicis S., Marzioni M. Hepatic fibrogenesis in response to chronic liver injury: novel insights on the role of cell-to-cell interaction and transition. Liver Int 2008, 28:1052-1064.
19. Wong G.L., Wong V.W., Choi P.C., Chan A.W., Chan H.L. Development of a non-invasive algorithm with transient elastography (Fibroscan) and serum test formula for advanced liver fibrosis in chronic hepatitis B. Aliment Pharmacol Ther 2010, 31:1095-1103.
20. Yu H., Li Q., Zhou X., Kolosov V.P., Perelman J.M. Role of hyaluronan and CD44 in reactive oxygen species-induced mucus hypersecretion. Mol Cell Biochem 2011, 352:65-75.
21. Mehta P., Ploutz-Snyder R., Nandi J., Rawlins S.R., Sanderson S.O., Levine R.A. Diagnostic accuracy of serum hyaluronic acid, FIBROSpect II, and YKL-40 for discriminating fibrosis stages in chronic hepatitis C. Am J Gastroenterol 2008, 103:928-936.
22. Shaheen A.A., Myers R.P. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology 2007, 46:912-921.
23. Nunes D., Fleming C., Offner G., et al. Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection. Am J Gastroenterol 2010, 105:1346-1353.
24. Wurtz S.O., Schrohl A.S., Sorensen N.M., et al. Tissue inhibitor of metalloproteinases-1 in breast cancer. Endocr Relat Cancer 2005, 12:215-227.
25. Ratziu V., Massard J., Charlotte F., et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006, 6:6.
26. Martinez-Lopez E., Nuno-Gonzalez P., Ruiz-Madrigal B., et al. Apolipoprotein AI and apolipoprotein E mRNA expression in peripheral white blood cells from patients with orthotopic liver transplantation. Liver Int 2007, 27:930-937.
27. Tsai M.H., Peng Y.S., Chen Y.C., et al. Low serum concentration of apolipoprotein A-I is an indicator of poor prognosis in cirrhotic patients with severe sepsis. J Hepatol 2009, 50:906-915.
28. Kumar M., Kumar A., Hissar S., et al. Hepatic venous pressure gradient as a predictor of fibrosis in chronic liver disease because of hepatitis B virus. Liver Int 2008, 28:690-698.
29. Chan H.L., Wong G.L., Choi P.C., et al. Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. J Viral Hepat 2009, 16:36-44.
30. Gailhouste L., Le Grand Y., Odin C., et al. Fibrillar collagen scoring by second harmonic microscopy: a new tool in the assessment of liver fibrosis. J Hepatol 2010, 52:398-406.
31. Lee M.H., Cheong J.Y., Um S.H., et al. Comparison of surrogate serum markers and transient elastography (Fibroscan) for assessing cirrhosis in patients with chronic viral hepatitis. Dig Dis Sci 2010, 55:3552-3560.
32. Park S.H., Kim D.J., Cheong J.Y., et al. Noninvasive markers to diagnose cirrhosis in patients with HBeAg positive chronic hepatitis: do new biomarkers improve the accuracy?. Clin Biochem 2010, 43:877-881.
33. Cowan M.L., Rahman T.M., Krishna S. Proteomic approaches in the search for biomarkers of liver fibrosis. Trends Mol Med 2010, 16:171-183.
34. Paradis V. Glycomics: a new taste of cirrhosis marker. J Hepatol 2005, 43:913-914.
35. Baranova A., Liotta L., Petricoin E., Younossi Z.M. The role of genomics and proteomics: technologies in studying non-alcoholic fatty liver disease. Clin Liver Dis 2007, 11:209-220.
36. Kim J.E., Lee J.Y., Kim Y.J., et al. Acoustic radiation force impulse elastography for chronic liver disease: comparison with ultrasound-based scores of experienced radiologists, Child-Pugh scores and liver function tests. Ultrasound Med Biol 2010, 36:1637-1643.
37. Rustogi R., Horowitz J., Harmath C., et al. Accuracy of MR elastography and anatomic MR imaging features in the diagnosis of severe hepatic fibrosis and cirrhosis. J Magn Reson Imaging 2012, 35:1356-1364.